Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review

Ko, Justine S.; Johnson, Sheeva; Dave, Maneesh

doi:10.3390/biom11010082

Cited by 49 publications

(47 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cells sprinted into the clinic stage center due to their features of versatile development potential, self-renewal, allogenic compatibility, and immunomodulatory effects. MSCs are currently being widely tested as a cellular therapy in chronic intestinal diseases, including IBD, and showed promising clinical outcomes with unmet optimization and improvement [28][29][30], such as in vivo low level of MSC recruitment, and persistence decreased their therapeutic efficacy [31].…”

Section: Discussionmentioning

confidence: 99%

Wogonin Strengthens the Therapeutic Effects of Mesenchymal Stem Cells in DSS‐Induced Colitis via Promoting IL‐10 Production

Xie

Zhu

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) are prevalent and debilitating diseases; their clinical remedy is desperately unmet. Mesenchymal stem cells (MSCs) are pluripotent stem cells with multiple immunomodulatory effects, which are attributed to their efficacy in the IBD rodent model. Optimization of MSC regimes in IBD is a crucial step for their further clinical application. Wogonin is a flavonoid-like compound, which showed extensive immunomodulatory and adjuvant effects. This research is aimed at investigating whether and how Wogonin boosted the therapeutic efficiency of MSCs on DSS-induced colitis. Our results showed that the MSC treatment with Wogonin significantly alleviated the intestinal inflammation in IBD mice by increased IL-10 expression. In vitro experiments, Wogonin obviously raised the IL-10 production and ROS levels of MSCs in a dose-dependent manner. Meanwhile, western blot data suggested Wogonin improves the IL-10 production by inducing transcript factor HIF-1α expression via AKT/GSK3β signal pathway. Finally, the favorable effects of Wogonin on MSCs were confirmed by IL-10 blockade experiment in vivo. Together, our results suggested that Wogonin significantly increased the IL-10 production and enhanced the therapeutic effects of MSCs in DSS-induced colitis. This work suggested Wogonin as a novel optimal strategy for MSC clinical application.

show abstract

Section: Discussionmentioning

confidence: 99%

Wogonin Strengthens the Therapeutic Effects of Mesenchymal Stem Cells in DSS‐Induced Colitis via Promoting IL‐10 Production

Xie

Zhu

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…The author observed BM-MSCs treatment decelerated the loss of renal allograft function [ 27 ]. The systematic review about MSC therapy with 32 studies for Inflammatory Bowel Diseases (IBD) revealed that MSCs are proving to be a very exciting addition to the limited therapies available for IBD [ 28 ]. A systematic review about HSC transplantation in SLE with 15 studies revealed that most of the studies showed remission in the majority of patients.…”

Section: Resultsmentioning

confidence: 99%

“…Such as stem cell transplantation results in satisfactory clinical response in SLE patients; MS patients and IBD et al. [ 21 , 28 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

A review and update for registered clinical studies of stem cells for non-tumorous and non-hematological diseases

Chen

Luo

Tian

et al. 2021

Regenerative Therapy

View full text Add to dashboard Cite

Objective To provide consultative information on selecting potential indications of stem cells in the treatment of non-tumorous and non-hematopoietic system conditions, we screened the clinical trials on website: http://www.clinicaltrials.gov . Methods A literature search was conducted using the National Institute of Health (NIH) website ( http://www.clinicaltrials.gov ) from May 10th, 2012 to Oct 13th, 2020 with stem cells as an intervention in human trials for non-tumorous and non-hematological conditions. There was no restriction for language, research location, and research race. Results and conclusion Search terms initially found a total of 3576 articles. Firstly, 138 terminated or suspended studies were excluded and further 24 repeated studies were excluded. Secondly, 987 tumorous and hematopoietic conditions-related studies were excluded. Lastly, 1218 studies were excluded without stem cell therapy as their primary purpose. A total of 1209 research studies were entered into the analysis and reviewed. The top 4 diseases were about motor system diseases 229 (19.28%). In addition, 206 (17.34%) studies were related to central nervous system (CNS) diseases. 140 (11.78%) were autoimmune diseases or graft-versus-host disease (GVHD) after organ transplantation. 129 (10.86%) were about respiratory system diseases, among them, 44.19% projects were about new coronary pneumonia (NCP). The main cell types used in various diseases are Mesenchymal Stem Cells (MSCs), bone marrow stem cells (BM-SCs), peripheral blood stem cells (PBSCs), hematopoietic stem cells (HSCs), adipose stem cell (ASCs) and precursor cells.

show abstract

“…Significant numbers of other clinical trials are dealing with the use of MSCs' immunomodulatory properties as standalone therapy for various diseases and conditions associated with overactivated immune systems. MSCs were tested for treatment of rheumatoid arthritis and osteoarthritis [225], multiple sclerosis [226], inflammatory bowel disease [227], systemic lupus erythematosus [228], diabetes mellitus [229], among other pathologies. In most reported cases, good safety profiles and encouraging outcomes were reported.…”

Section: Translation To the Clinicmentioning

confidence: 99%

Hematopoiesis during Ontogenesis, Adult Life, and Aging

Belyavsky

Petinati

2021

IJMS

View full text Add to dashboard Cite

In the bone marrow of vertebrates, two types of stem cells coexist—hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). Hematopoiesis only occurs when these two stem cell types and their descendants interact. The descendants of HSCs supply the body with all the mature blood cells, while MSCs give rise to stromal cells that form a niche for HSCs and regulate the process of hematopoiesis. The studies of hematopoiesis were initially based on morphological observations, later extended by the use of physiological methods, and were subsequently augmented by massive application of sophisticated molecular techniques. The combination of these methods produced a wealth of new data on the organization and functional features of hematopoiesis in the ontogenesis of mammals and humans. This review summarizes the current views on hematopoiesis in mice and humans, discusses the development of blood elements and hematopoiesis in the embryo, and describes how the hematopoietic system works in the adult organism and how it changes during aging.

show abstract

Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review

Cited by 49 publications

References 55 publications

Wogonin Strengthens the Therapeutic Effects of Mesenchymal Stem Cells in DSS‐Induced Colitis via Promoting IL‐10 Production

Wogonin Strengthens the Therapeutic Effects of Mesenchymal Stem Cells in DSS‐Induced Colitis via Promoting IL‐10 Production

A review and update for registered clinical studies of stem cells for non-tumorous and non-hematological diseases

Hematopoiesis during Ontogenesis, Adult Life, and Aging

Contact Info

Product

Resources

About